A Study of BL-M07D1 vs Pembrolizumab-platinum Chemotherapy in First-line Treatment of HER2-mutant Advanced or Metastatic Non-squamous NSCLC

NCT07178795 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

440

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-squamous Non-small Cell Lung Cancer

Interventions

DRUG: BL-M07D1
DRUG: Pembrolizumab
DRUG: Pemetrexed
DRUG: Carboplatin
DRUG: Cisplatin

Sponsor

Sichuan Baili Pharmaceutical Co., Ltd.

Collaborators

Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.